Status:

TERMINATED

Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Lead Sponsor:

Nantes University Hospital

Conditions:

Multiple Myeloma

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

The objective of this study is to evaluate the efficacy and safety of Velcade plus dexamethasone used as induction chemotherapy prior to autologous transplantation.

Eligibility Criteria

Inclusion

  • diagnosis of MM according to the SWOG criteria (annex 1)
  • previously untreated (localized radiotherapy is allowed)
  • symptomatic MM stage II or III according to Durie-Salmon staging system (annex 2) or stage I with one symptomatic osteolytic lesion
  • with measurable levels of paraprotein in the serum (\> 1g/dl) or in the urine (\> 0.2g/24h)
  • age \< 75 years
  • able to understand and to given an informed consent
  • male, female without childbearing potential or negative urine pregnancy test within 72 hours prior to beginning the treatment. Women of childbearing potential must be following adequate contraceptive measures.
  • no active systemic infection. In the presence of any active systemic infection, adequate broad-spectrum or organism-specific antibiotic coverage must be administered. Patients must be a febrile with stable vital signs while receiving antibiotics for at least 48 hours prior to beginning the treatment with Velcade plus dexamethasone.

Exclusion

  • life expectancy \< 2 months
  • ECOG performance status \> 2 (annex 3)
  • proven amyloidosis
  • positive HIV serology
  • antecedents of severe psychiatric disease
  • severe diabetes contraindicating the use of high-dose corticoïds
  • \> NCI grade 2 peripheral neuropathy (Annex IV)
  • serum biochemical values as follow
  • creatinin level \> 200mmol/l
  • bilirubin, transaminases or gGT \> 3 the upper normal limit
  • use of any experimental drugs within 30 days of baseline

Key Trial Info

Start Date :

August 1 2003

Trial Type :

INTERVENTIONAL

End Date :

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT00337506

Start Date

August 1 2003

Last Update

June 16 2006

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Jean-Luc HAROUSSEAU

Nantes, France, 44093